| Name | Title | Contact Details |
|---|
Sovereign Bank is the largest tribally-owned bank in the United States, owned by the Citizen Potawatomi Nation. The bank focuses on community-driven banking, emphasizing relationships, trust, and financial empowerment for both Native and non-Native customers. It was rebranded in 2023 to honor its tribal heritage and continues to prioritize financial stability and self-sufficiency for families and businesses. With roots tracing back to the acquisition of First Oklahoma Bank in 1984, Sovereign Bank combines the capabilities of a large bank with a small-town, relationship-focused approach. The bank promotes personalized banking solutions tailored to individual needs and offers a Financial Learning Hub for education and empowerment. Sovereign Bank is dedicated to serving all communities and investing in people, fostering opportunity and stability for future generations.
The Big Biscuit, founded in 2000, is an All-American breakfast and lunch concept focusing on freshly prepared classic comfort food consistently served with generous portions in a family-friendly environment. The Big Biscuit has 27+ locations in Kansas, Missouri, Oklahoma, and Arkansas
Manufacturing and sale of industrial precision balls, rollers, cages and sheet metal parts used for bearing and other applications. Manufacturing and sale of ball screws, and large scale blowers.
BLUEBONNET® Abstract and Title is a locally owned and operated title company located in Brenham and Bellville Texas and serving adjacent counties. We are fully licensed in Washington, Austin, Fayette, Brazos, Grimes, Robertson, Colorado, and Lee Counties, and serve the adjoining counties (such as Waller), regularly. BLUEBONNET® was established to provide a title company focused on the customer and the community. BLUEBONNET® sets itself apart from its competitors by providing excellent customer service in all aspects of the real estate transaction. Our customers actually enjoy the real estate closing process – we know you will too.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.